Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: Int J Cancer. 2019 Oct 18;146(12):3320–3328. doi: 10.1002/ijc.32693

Table 2.

Average type-specific HPV prevalence (percentage) across all study visits by HIV-status/CD4 count, and GEE prevalence ratios (PRs) that contrast type-specific prevalence rates in HIV[+] women (with CD4 < 200) vs. HIV[−] women

HIV[+]
HPV type Phylogenetic Group Rank of Lowest PRs2 HIV[−]
n = 901		 All
n = 2,566		 CD4+ >500
n = 816		 CD4+ 200–500
n = 1,066		 PR: HIV[+] vs. HIV[−] PR: HIV[+] <200 vs. HIV[−] ptrend3
6 α10 6 0.49 1.97 0.70 1.86 2.52 4.78 <0.0001
11 α10 0.11 1.23 0.48 1.03 8.21 19.24 <0.0001
161 α9 2 1.27 3.33 1.85 3.35 2.26 3.85 <0.0001
181 α7 9 0.74 3.12 1.40 2.82 3.25 5.81 <0.0001
26 α5 0.10 0.57 0.12 0.42 4.24 10.84 <0.0001
311 α9 3 0.59 2.44 1.29 2.31 2.96 4.86 <0.0001
32 α1 0.28 2.58 1.12 2.83 7.83 14.90 <0.0001
331 α9 0.43 2.81 1.32 2.86 5.46 9.94 <0.0001
351 α9 0.21 1.15 0.39 1.02 4.85 12.26 <0.0001
391 α7 0.22 1.18 0.25 0.95 5.15 15.94 <0.0001
40 α8 0.09 0.79 0.26 0.65 8.52 16.13 0.01
451 α7 0.55 2.83 1.64 2.29 4.58 8.26 0.001
511 α5 0.76 3.06 1.28 2.85 4.41 8.76 <0.0001
521 α9 0.57 2.93 1.73 2.51 4.92 10.53 <0.0001
53 α6 1.29 6.40 2.82 6.09 5.17 9.73 <0.0001
54 α13 0.29 2.71 1.52 2.38 9.44 16.51 0.0002
55 α13 0.08 0.68 0.39 0.62 7.12 12.60 0.01
561 α6 0.53 3.27 1.39 3.28 5.52 10.98 <0.0001
581 α9 0.99 5.11 2.13 5.29 6.98 12.81 <0.0001
591 α7 0.30 1.85 0.65 1.71 4.95 10.39 <0.0001
61 α3 0.77 6.51 3.86 6.45 8.53 13.84 <0.0001
62 α3 10 0.97 5.11 3.47 5.50 4.37 6.25 0.004
66 α6 0.38 2.37 1.59 3.04 10.15 18.03 0.0001
67 α9 0.15 0.44 0.24 0.31 8.15 13.44 0.25
681 α7 5 0.45 1.76 0.84 1.85 3.11 5.32 <0.0001
69 α5 4 0.00 0.39 0.22 0.61 2.32 5.03 0.08
70 α7 0.67 5.58 3.21 5.10 4.35 8.15 <0.0001
71 α15 1 1.28 3.44 1.79 3.33 1.83 1.78 0.12
72 α3 7 0.50 3.29 1.03 1.92 3.04 5.64 0.02
73 α11 0.00 1.63 1.45 2.22 7.39 15.41 <0.0001
81 α3 7 1.23 7.56 4.66 5.72 3.46 5.64 0.0001
82 α5 0.28 1.27 0.71 1.06 4.77 10.10 0.0001
83 α3 1.05 4.83 3.07 5.99 5.82 7.70 <0.0001
84 α3 0.49 3.02 1.74 3.56 11.36 21.78 <0.0001
85 α7 0.23 1.09 1.76 0.94 17.10 30.03 0.06
89 α3 0.15 0.59 0.24 1.09 8.73 23.12 0.0003
1

Carcinogenic.

2

The GEE prevalence ratios (PR) were adjusted for age, smoking, ever IDU, baseline lifetime number of male sexual partner, number of male sexual partners in past 6 months, and cervical treatment in past 6 months. CD4 was treated as a time-dependent covariate.

3

P-trend is based on average prevalence by CD4+ stratum among HIV+.